

100 Days Mission 3rd Implementation Report Launch Event: Speaker Biographies

In order of event programme

Photograph	Name	Biography
	Professor Rino Rappuoli Scientific Director of the Biotechnopolo di Siena Foundation and head of MAD Lab Toscana Life Sciences, Italy	Rino Rappuoli is Scientific Director of the Biotechnopolo di Siena Foundation and head of MAD Lab Toscana Life Sciences, Italy. He is also Honorary Professor of Vaccinology at Imperial College, London, and Senior Professor of Molecular Biology at the University of Siena. Prior positions held: Head R&D and Chief Scientist at GSK Vaccines, head of Vaccine R&D at Novartis, CSO at Chiron Corporation, head R&D at Sclavo. He earned his PhD in Biological Sciences at the University of Siena, Italy, and was visiting scientist at Rockefeller University and Harvard Medical School. He is elected member of US National Academy of Sciences (NAS), the American Academy of Arts & Sciences (AAAS), the American Institute for Medical and Biological Engineering (AIMBE), the European Molecular Biology Organization (EMBO), the Royal Society of London, the Accademia Nazionale dei Lincei. Awards received: Gold Medal by the Italian President, Albert B Sabin Gold Medal, Canada Gairdner International Award, European Inventor Award for Lifetime Achievement, Paul Ehrlich and Ludwig Darmstaedter Prize and the Robert Koch Award. He is President of the International Union of Microbiological Societies. He was nominated third most influential person worldwide in the field of vaccines (Terrapin). He has published 796 works in peer-reviewed journals and an H-index of 158.

		He introduced novel scientific concepts: genetic detoxification; cellular microbiology; reverse vaccinology; pangenome. Developed licensed vaccines: acellular pertussis containing a non-toxic mutant of pertussis toxin; first conjugate vaccine against meningococcus C; conjugate vaccines against meningococcus ACYW, MF59-adjuvanted seasonal and pandemic influenza. MF59 was the first vaccine adjuvant approved for human use after the aluminum salts; meningococcus B by reverse vaccinology; cell culture-based influenza vaccine, respiratory syncytial virus, CRM 197 as carrier of most conjugate vaccines. Founder of the GSK Vaccines Institute for Global Health (GVGH). Dr. Rappuoli is among the world scientific leaders dedicated to the sustainability of global health.
	Dr Sergio Iavicoli Director General of Communication and European and International Relations of the Ministry of Health, Italy	Sergio Iavicoli got his medical degree and Residency Program in Occupational Medicine at the University of Rome "Sapienza". He completed his PhD (Occupational Health and Industrial Toxicology), at University of Cagliari. He was Research Fellow at School of Public Health, University of California Berkeley. He was member, representing INAIL, of the National Technical Scientific Committee (CTS) for the Emergency of SARS-CoV2 Pandemic. Currently he is Director of the Directorate-General for Communication and European and International Relations of the Ministry of Health. Previously served as Director of the Research Department of Occupational and Environmental Medicine, Epidemiology and Hygiene of the Italian Workers' Compensation Authority (INAIL) and as Secretary General of the International Commission on

		Occupational Health (ICOH). He was President of the European Academy of Occupational Health Psychology (EAOHP). He served as Member of national/international Committees including the Advisory Committee of the Global Network of WHO Collaborating Centers in Occupational Health, Member of the Partnership for European Research on Occupational Safety and Health (PEROSH) Steering Committee. He is Member of the Editorial Board of several scientific journals, book series and encyclopedias. He was awarded as honorary fellow of the Royal College of Physicians of Ireland and fellow of the British Academy of Social Sciences. He is author of more than 290 peer-review and policy paper in journals with impact factor.
	Dr Jeremy Farrar Chief Scientist, WHO @JeremyFarrar	As Chief Scientist, Jeremy Farrar will oversee the work of the Science Division, bringing together experts and networks working in science and innovation from around the world to guide, develop and deliver high quality health policies and services to the people who need them most. Prior to joining WHO, Dr Farrar was Director of the Wellcome Trust. In his 9 years there, he oversaw a series of major reforms, restructuring and growth, with Wellcome now collaborating with partners around the world and focused on fundamental discovery research and three challenge areas of: infectious diseases; climate and health; and mental health, all with a commitment to ensuring that equity, diversity and inclusion are central to the science they support. Before joining Wellcome, Dr Farrar spent over 17 years as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Ho Chi Minh City in Viet Nam. His clinical and research interests have been in integrated

		health research across a range of infectious diseases and noncommunicable illness including emerging infections, influenza, infections of the brain, dengue, typhoid, malaria, tuberculosis, antimicrobial resistance, opportunistic infections related to HIV and stroke. Dr Farrar was the founding chair of WHO's R&D Blueprint and the founding director of the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) that led on to the work of the RECOVERY Trial and the UK COVID-19 Genomics UK Consortium. Dr Farrar trained in neurology and infectious diseases in London, Edinburgh and Oxford in the United Kingdom and in Melbourne in Australia. He has a PhD in Immunology from the University of Oxford in the United Kingdom in partnership
	Dr Victor Dzau President, US National Academy of Medicine; 100DM Science and Technology Expert Group Co-Chair He/Him/His @VictorDzau	Victor Dzau is President of the US National Academy of Medicine (NAM), Vice-Chair of the US National Research Council, Chancellor Emeritus of Duke University, and past CEO of Duke Health System. Previously, he was Professor and Chairman of Medicine at both Harvard and Stanford Universities. Dr. Dzau is recognized globally for a long and highly decorated career as a scientist, administrator, and leader. His research laid the foundation for development of lifesaving drugs known as ACE inhibitors, used globally to treat high blood pressure and congestive heart failure. Dzau brings a global perspective and activist orientation to the NAM. He designed and leads important initiatives including the Commission on a Global Health Risk Framework, Roadmap for Healthy Longevity, the International Human Gene Editing Initiative; Vital Directions for Health and Health Care; Confronting the

		Opioid Crisis; and the Grand Challenge in Climate Change and Human Health. A leader in global health, Dzau serves on the Global Preparedness Monitoring Board, is a principal of the ACT Accelerator, was advisor to G20 High Level independent panel on Financing for Pandemic Preparedness and Response, co-chaired the G20 Scientific Panel on Global Health Security, and serves as an advisor to the G7 (Japan) Health Task Force. He co-leads the World Economic Forum Regional Vaccine Manufacturing Collaborative and is co-chair of the Science and Technology Expert Panel for the Independent Pandemic Preparedness Secretariat for the 100 Day Mission. Among his many honors and recognitions are the Gustav Nylin Medal from the Swedish Royal College of Medicine, the Research Achievement Award from the American Heart Association, the Ellis Island Medal of Honor, the Poulzer Prize of the European Academy of Sciences and Arts, the Henry Freisen International Prize, and the Porter Prize of the University of Pittsburgh. He was made an Honorary Citizen of Singapore, the highest honor bestowed to a foreign individual. He has received 18 honorary doctorates.
--	--	--



Professor Teresa Lambe OBE

Calleva Head of Vaccine Immunology & Professor of Vaccinology & Immunology at University of Oxford

@jenneratingVacc

Teresa Lambe is the Calleva Head of Vaccine Immunology and a Professor of Vaccinology & Immunology at the University of Oxford. She is leading a research group which improves human health by controlling disease through vaccination – stopping epidemics before they become pandemics. Prof Lambe is one of the Principal Investigators overseeing the Oxford/AstraZeneca vaccine programme; she co-designed the vaccine in January 2020, led the preclinical studies, and then oversaw the delivery of the immune results needed to support regulatory approval in late 2020. The vaccine has played a pivotal role in the fight against COVID-19 – estimated to have saved >6 million lives globally. Prof. Lambe was appointed as an honorary OBE for her services to Sciences and Public Health in the 2021 Queen’s Birthday Honours and received the Presidential Distinguished Service Award for the Irish Abroad in 2022.

Prof Lambe’s group are particularly interested in delineating the protective immune response post infection and using these findings to rationally design vaccination strategies to prevent disease. The establishment of long-lived immunity, post vaccination, is also critically important in protecting against infectious disease and is a key focus of the research. The Lambe group is currently developing and testing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Ebola virus, Marburg virus Disease and Coronaviruses. A number of these vaccines have progressed to clinical

		trial assessment, including a vaccine against Ebola virus diseases (ChAdOx1 biEBOV); in late 2022, this vaccine was one of three chosen by the WHO to be included in a ring vaccination protocol against the Sudan ebolavirus outbreak in Uganda. In 2023, the team's candidate vaccine against Marburg virus disease was selected by WHO for inclusion in trials to combat Marburg virus disease.
	Dr Mariângela Batista Galvão Simão Director-president of the Instituto Todos pela Saúde	Dr Mariângela Batista Galvão Simão is the director-president of the Instituto Todos pela Saúde, a non-profit organization based in São Paulo, Brazil, which focuses on supporting the national health system for pandemic preparedness. She was WHO's Assistant Director-General for Access to Medicines and other Health Products from 2017 until 2022. She was previously Director of Community Support, Social Justice and Inclusion at UNAIDS. In addition to her work at UNAIDS, she brings more than 30 years of experience working in the Brazilian public health system, including as Director of the National STD/AIDS and Viral Hepatitis Department in the Brazilian Ministry of Health, where she led successful price negotiations with pharmaceutical companies to lower the price of HIV medication.



Dr Ruxandra Draghia-Akli, MD, PhD

Former Global Head, Global Public Health R&D at Johnson & Johnson

Ruxandra Draghia-Akli is an accomplished pharmaceutical, life sciences innovator and inspirational leader. She was Global Head, Global Public Health R&D at Johnson & Johnson, the industry's first business unit dedicated to advancing innovation-driven solutions to major public health threats disproportionately impacting low-to-middle-income countries. Ruxandra and her team advanced new solutions leveraging discovery, development, and technology capabilities, and pioneer novel global collaborations, including the J&J Centers for Global Health Discovery. Ruxandra served as the co-chair of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Therapeutics Clinical Working Group. Previously, Ruxandra led Medical and Scientific Affairs for vaccines at Merck and worked for the European Commission where she oversaw research and innovation initiatives. Ruxandra holds a M.D. from Carol Davila University and a Ph.D. in human genetics from the Romanian Academy of Medical Sciences. She undertook doctoral training at University Rene Descartes (Paris, France) and a postdoctoral training (Houston, Texas), with a focus on rare diseases, molecular biology, gene therapy and novel vaccines. Ruxandra has authored and co-authored more than 100 papers and holds over 200 patents.



Dr Sergio Carmona

Acting CEO and Chief Medical Officer

Dr Sergio Carmona joined FIND in 2019 and is the current Chief Medical Officer and (interim) CEO. Prior to joining FIND, Sergio spent over a decade at the National Health Laboratory Service (NHLS) in South Africa, where he specialized in molecular diagnostics and treatment monitoring for early infant diagnosis, HIV drug resistance and associated co-infections. A haematologist by training, Sergio has been involved in technical committees and initiatives led by WHO, the US Centers for Disease Control and Prevention, the African Society of Laboratory Medicine and the South African National Department of Health. Sergio earned his medical degree (MBBCh) from the University of Witwatersrand before doing a Pathology Specialization (FCPath) in 2009, earning a PhD in Molecular Medicine and Haematology in 2018.



Dr Mona Nemer

Chief Science Advisor of Canada

@ChiefSciCan

Dr. Mona Nemer was first appointed Canada’s Chief Science Advisor in 2017, reappointed in 2020, and again in 2022. Prior to this role, Dr. Nemer was Professor and Vice-President of Research at the University of Ottawa and Director of the school’s Molecular Genetics and Cardiac Regeneration Laboratory.

Dr. Nemer has served on various national and international advisory committees and boards, including as an Executive Committee Member of the COVID-19 Immunity Task Force as well as an ex-officio member of the COVID-19 Vaccine Task Force and the Industry Strategy Council. During her mandate, she has helped to expand and diversify science advice to government by establishing a multidisciplinary network of federal science advisors, founding a pan-Canadian youth council to provide evidence-based input on scientific issues affecting young people, and helping to create the Interdepartmental Indigenous STEM Cluster (I-STEM) to inform and advance Indigenous aspirations and innovation in natural science stewardship. Dr. Nemer has also promoted free, open, and responsible use of science in government through the creation of a model policy on scientific integrity and a roadmap for open science to guide efforts in making federal research available to Canadians. She has provided science advice on numerous issues ranging from research infrastructure to the COVID-19 pandemic.

Dr. Nemer holds a PhD in Chemistry from McGill University and has done post-doctoral training in molecular biology at the Montréal Clinical Research Institute and Columbia University. Prior to joining the

		University of Ottawa, she was a Professor of Pharmacology at the Université de Montréal and directed the Cardiac Genetics Unit at the Montréal Clinical Research Institute.
	Dr Philippe Duneton Executive Director, Unitaid @DrDuneton	A French national, Philippe has more than 25 years' experience in the fields of HIV/AIDS, infectious and tropical diseases and public health. Philippe has been at Unitaid since its creation in 2006. As Executive Director a.i, he has led Unitaid's response to the COVID-19 pandemic, playing a vital role as the co-lead of the therapeutics arm of the Access to COVID Tools Accelerator. Previously, he was a practicing doctor at Hospital "La Pitié Salpêtrière" in Paris (Infections Diseases Department) and was twice advisor to the French Ministry of Health under Minister Bernard Kouchner. He was the head of the Mission against HIV/AIDS and harm reduction for l'Assistance publique – Hôpitaux de Paris (AP-HP) and led the French regulatory agency for medicines and health products. He also chaired the Board of the European Medicines Agency. Philippe holds a Master's degree in Public Health and is a Doctor.
	Ms Pushpa Vijayaraghavan Director and Practice Lead, Healthcare & Innovation Advisory, at Sathguru Management Consultants; MPP Board Member She/her @pushpa_sathguru	Pushpa Vijayaraghavan is Director and Practice Lead, Healthcare & Innovation Advisory, at Sathguru Management Consultants, a consultancy firm with market leading presence at the intersection of strategy, innovation, transactions and policy in life sciences. Pushpa is also a member of the Governance Board of the Medicines Patent Pool. Pushpa leads Sathguru's engagement with global biopharma industry and has shaped growth strategy for companies across specialty pharma and generics, and

		across product categories – small molecules, biologics, peptides, vaccines et al. Pushpa has also advised marque private equity funds on segment investment strategy and evaluation of investment opportunities. Pushpa has stewarded IP licensing and technology transfer for institutions across global regions; and has led more than 30 transactions across the spectrum of platform and product licensing for global / regional rights. Pushpa has been deeply engaged in supporting enabling policy frameworks for innovation funding and biopharma sector development: and has been involved across geographic regions in efforts around regional value chain development for pharma and biotech. Pushpa has also been a Senior Biopharma Sector Expert retained by the World Bank. Pushpa's past experience includes working with the Technology Transfer Office at the University of Michigan and corporate consulting with the life sciences industry in PricewaterhouseCoopers Private Limited (PwC) and Ernst & Young. She is a Registered Technology Transfer Professional (RTTP, and one among the first ten technology transfer professionals from India to gain the RTTP accreditation. Pushpa is an MBA from the University of Michigan (Ann Arbor), USA, and an Indian Chartered Accountant. Pushpa also holds a Certificate in Innovation Policy from the Ford School of Public Policy and is a Danida Fellow (Danish Government fellowship) on Innovation Management and IP commercialization.
--	--	---

	Dr Samia Saad Executive Director of Resource Mobilisation & Investor Relations at the Coalition for Epidemic Preparedness Innovations (CEPI) She/Her @samiaGS	Samia is Executive Director of Resource Mobilisation & Investor Relations at the Coalition for Epidemic Preparedness Innovations (CEPI). Samia and her team are responsible for the strategic engagement with sovereign governments, philanthropic foundations, multi-lateral development banks and a wide range of other stakeholders to ensure CEPI’s sustainability. Prior to taking on her role at CEPI, Samia was the Bill & Melinda Gates Foundation (BMGF) representative on the CEPI Investor Council and observer to the Board. During the previous seven years, Samia developed and lead BMGF’s Global Health R&D and Epidemic Preparedness Policy & Advocacy strategy. Prior to that, Samia spent many years as a technical advisor to EU donor governments and multi-lateral health agencies, defining science and research priorities and conducting policy analysis for better access to medicines and vaccines in low-income countries. Samia has also worked as a medicines policy analyst at the WHO in Geneva and Cairo and as Strategy Manager at the UK BioIndustry Association (BIA) where she led initiatives that focused on securing an enabling research policy environment in the EU, fostering global bioscience partnerships and developing research & innovation strategies. Samia holds a BSc. (Honours) in Biochemistry from Imperial College, London and an MSc. in International Health Policy & Health Economics from the London School of Economics & Political Science and spent several years as biomedical researcher conducting doctoral studies at King’s College London and post doctoral studies Harvard Medical School.
---	--	---



Dr Marco Cavaleri

Head of Office, Health Threats and vaccines strategy, European Medicines Agency

Marco Cavaleri is Head of Office, Health Threats and vaccines strategy. He is the Chair of EMA COVID-19 Task Force (ETF) and responsible for EMA activities for emergent pathogens, vaccines and AMR. He serves in different advisory groups at WHO, including PDVAC, AMR priority pathogens and R&D Blueprint SAC and clinical trials working group. Marco Cavaleri is a Pharmacologist who spent several years in industry in R&D mainly in the area of anti-infectives covering different positions in preclinical and clinical development of new antibacterial, antitubercular and antifungal agents. He has expertise in microbiology, animal models, PK/PD and clinical trial design for antibacterial and TB drugs, from early phase to late stage clinical trials. He is involved in several areas of vaccines and innovative therapies development, such as bacteriophages, that could tackle AMR. He has been driving the EMA AMR strategy on human medicines since 2009 including the international partnerships that lead to alignment of clinical trials requirements for new antibacterial agents with FDA, PMDA and HC. He is co-author of several publications related to AMR, TB, antibiotics, vaccines and phages.

	Shingai Machingaidze Acting Chief Science Officer, Africa CDC; 100DM Science and Technology Expert Group Co-Chair	Ms Machingaidze is an epidemiologist and public health specialist, who is Ag. Chief Science Officer at Africa CDC and the CPHIA Secretariat Lead. She has fourteen years of experience in the public health and clinical research fields, where she has led workforce development programs to build the capacity of Africa-based scientists and institutions. Her expertise includes conducting and managing clinical trials and clinical research; managing research grants and finances; advising and supporting public health programmes; as well as managing strategic partnerships and engagements with national, regional and international agencies. Shingai previously worked with the European Commission funded European and Developing Countries Clinical Trial Partnership (EDCTP), the Medical Research Council the National Institute of Communicable Diseases in South Africa, as well as the University of Cape Town. She is an alumna of ADVAC (Advanced Course of Vaccinology), a member of faculty for the Vaccines for Africa (VACFA) Annual Vaccinology Course, a Future Africa Forum Fellow as well as an Advisory Committee Member for the Clinical Trials Community.
---	--	--



Aggrey Aluso Odhiambo

Director, Africa Region for the Pandemic Action Network (PAN) and the Executive Director of Resilience Action Network Africa (RANA)

He/Him

@aggrealuso

Aggrey Aluso is the Director, Africa Region for the Pandemic Action Network (PAN) and the Executive Director of Resilience Action Network Africa (RANA). He is also the global policy lead for PAN. He is currently overseeing the operationalization of RANA to emerge as a vibrant and effective advocacy Hub to champion Africa centric, globally facing Resilience agenda encompassing the interconnected issues of Pandemic Preparedness and response, climate change and its impact on health as well as galvanizing and enhancing African voices in shaping global health governance issues.

Previously, Aggrey worked as a senior manager at the Open Society Initiative for Eastern Africa, leading the Health and Rights program, where he provided thought leadership in advancing advocacy (directly and through grant making) in addressing the structural and systemic barriers that hinder equitable access to health as democratic right. During the COVID pandemic, Aggrey led the OSF Africa team in its response, supporting strategic advocacy, directly and through grant making to advance equitable access to pandemic countermeasure including Vaccines, therapeutics and diagnostics as well addressing the intersectional justice challenges that were inherent in the pandemic response.

Aggrey also had an instrumental stint at Terre's des Hommes where he served as the Technical Expert Lobby and Advocacy for the multi-agency, tri-continental advocacy initiative. Hitherto, he worked as the Technical Manager – Policy & Advocacy for the University of Manitoba's global institute for public health seconded to Kenya's Ministry of health (HIV response). Prior to that,

		he served as the inaugural Country Advocacy and Campaigns Manager for Plan International, Kenya Country office where he set up the advocacy and campaign portfolio to buttress efforts to advance child rights in Kenya and Africa through strategic liaison with Plan Africa regional and global offices. He is thus a seasoned social justice advocate with expansive experience, spanning over 20 years in advancing intersectional justice, using citizen led, rights-based advocacy efforts. Aggrey holds advanced degree in Gender and development from university of Nairobi and is also a recipient of various certificates for strategic professional courses including from INSEAD on Leading for results, certificate in Policy and Legislative drafting by University of Johannesburg and TCA.
	Dr Renu Swarup (Virtual) Former Secretary, Department of Biotechnology Ministry of Science & Technology, Government of India @RenuSwarup	Dr Renu Swarup, is the Former Secretary, Department of Biotechnology (DBT), Government of India. Having served in Department of Biotechnology for over 30 years, she was also the Chairperson of Biotechnology Industry Research Assistance Council (BIRAC), She also held the Additional Charge of Secretary Department of Science & Technology for a short period. A PhD in Genetics and Plant Breeding, She did her Post Doctoral Research at The John Innes Centre, Norwich UK, Dr. Renu Swarup has been instrumental in the planning and implementation of some major National programmes. As a Science Manager issues related to policy planning and implementation were a part of her assignment. She was actively engaged in the formulation of National Biotechnology Vision and Strategy in 2001, 2007 and 2015 and 2021. She was also a

		member of the Task Force on Women in Science constituted by the Scientific Advisory Committee to the Prime Minister. As the Secretary of Government of India, Department of Biotechnology, she led a Network of 16 Autonomous Research Institutes, 2 Public Sector Undertaking and a R&D Network of more than 5000 projects across more than 100 research institutes, Universities and Laboratories. In the recent COVID Pandemic situation she led the COVID Vaccine, Diagnostic and Genome sequencing Mission. The Public Sector BIRAC, for which she was the founding Managing Director and then Chairperson, has supported more than 5000 Startups and over 75 Incubators. A Fellow of the National Academy of Sciences (NASI) India, A Life Member of Trust for Advancement of Agricultural Sciences (TAAS) and a Member of the Organization for Women in Science for the Developing World (OWSD), she was awarded the “BioSpectrum Person of the Year Award” in 2012. “National Entrepreneurship Awards 2017”, TiE Women Enabler Award 2018, “Dr. P. Sheel Memorial Award” 2018 by NASI and the TWAS Regional Office Prize on Science Diplomacy in 2018. She has been awarded the Agriculture Research Leadership Award 2019, Smt. Chandaben Mohanbhai Patel VASVIK Award for Women Scientific & Chemical science & Technology 2020-21, Lifetime Achievement Award for Biotech Policy maker—2021 by Golden Jubilee Women Biotech Park. She was also recognised as Business world women 2019 & 2020. She is
--	--	---

		also a recipient of Y B Chavan National Award 2021 for Public service. She received the Dr B S Bajaj Memorial FABA Excellence Award-2023. She is currently the Vice Chair of the International Centre for Antimicrobial Resistance Solutions (ICARS) Copenhagen, Denmark and also a Member of the National Start up Advisory Council, Govt of India. She is also the Scientific Expert on the Advisory Boards of the International Pandemic Preparedness, Govt of UK ; G7 Global Health Multistakeholder Group and the Chair of the Govt of India Expert Group on Preparedness for Future Pandemics.
	Thomas Cueni Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)	Thomas Cueni has led IFPMA since 2017, during which time he has been instrumental in establishing cross sectoral programs designed to tackle the biggest global health challenges. This includes establishing the \$1bn AMR Action Fund to support the development of new antibiotics; as Chair of the AMR Alliance; as a member of the Board of City Cancer Challenge; and as the industry's representative on the Access to COVID-19 Tools (ACT) Accelerator. Leading the IFPMA through the COVID-19 pandemic, Thomas galvanised the industry to develop the Berlin Declaration – the pharmaceutical industry's blueprint to deliver equitable access to vaccines, treatments, and diagnostics in future pandemics. Thomas is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics. He is also a member of the Business Advisory Group established by the Director General of the World Trade Organization.

		Prior to joining IFPMA, Thomas was Secretary General of Interpharma, the trade association representing Switzerland's research-based pharmaceutical industry; Secretary of the Dolder Group, precursor of what's now the BCR; and served on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Thomas began his career as a journalist, as London correspondent for the Basler Zeitung and Der Bund, before serving as a Swiss diplomat in Paris (OECD) and Vienna (IAEA, UNIDO). Thomas has a master's degree in economics from the University of Basel and another in politics from the London School of Economics. He also studied at the Geneva Graduate Institute for International Studies.
--	--	--